YONDELIS® was studied in patients with unresectable or metastatic liposarcoma and leiomyosarcoma who had been treated with a prior anthracycline-containing regimen.
YONDELIS® has an established safety profile.
DOSING AND ADMINISTRATION
MECHANISM OF ACTION
YONDELIS® mechanism of action.
Janssen CarePath is a comprehensive support program to help your patients start and stay on therapy and assist with access and affordability questions.
Information regarding specialty distributors authorized to sell YONDELIS®.
Information for patients and caregivers about what to expect during treatment with YONDELIS®.